Product
Supplier
Encyclopedia
Inquiry
Home > News > Market Flash > The latest development of PROTAC worldwide

The latest development of PROTAC worldwide

yaozh.com 2022-10-31

Focus on the most cutting-edge research results in the field of protein degradation and catch the latest developments in the PROTAC market? It's all in the five-minute "Today's PROTAC Headlines" series of tweets from Minox's ReThinking PROTAC platform.

 

Recently, Kymera Therapeutics Publishes Recent Patent for SMARCA degrader (WO 2022/125804 A1), Ram Sabnis (Smith, Gambrell & Russell LLP, "The patent was refined and briefly analyzed in ACS Medicinal Chemistry."

 

1, represents the molecule

屏幕截图 01

 

2. Targets and indications

Target: Switch/Sucrose Non-Fermentable (SWI/SNF)-Related, Matrix-Associated, Actin-Dependent Regulator of Chromatin, Subfamily A (SMARCA), including SMARCA2, SMARCA4, PB1, etc.

 

◆ Indications: Cancer

 

3. Synthetic pathways

屏幕截图02


4. Biological activity

屏幕截图03

 

Disclaimer: ECHEMI reserves the right of final explanation and revision for all the information.
Comment
Comment

Trade Alert

Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.